Tuesday - November 26, 2024
GE HealthCare Announces FDA Approval of Flyrcado Injection PET Radiotracer for Enhanced Diagnosis of Coronary Artery Disease
September 28, 2024
CHICAGO, Illinois, Sept. 28 (TNSres) -- G.E. HealthCare issued the following news release:

* * *

* GE HealthCare's FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology today

* With a half-life over ten times longer than currently approved cardiac PET radiotracers, Flyrcado brin . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products